<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881828</url>
  </required_header>
  <id_info>
    <org_study_id>T1DX-17-2013-506</org_study_id>
    <secondary_id>17-2013-506</secondary_id>
    <nct_id>NCT01881828</nct_id>
  </id_info>
  <brief_title>Metformin Therapy for Overweight Adolescents With Type 1 Diabetes</brief_title>
  <official_title>A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the proposed research is to evaluate the efficacy and safety of the use of
      metformin in addition to standard insulin therapy in overweight and obese children and
      adolescents, age 12-&lt;20 years, with type 1 diabetes for at least 1 year. Secondary objectives
      are to assess the effect of metformin on C-peptide levels, a measure of how much insulin is
      still being produced by the beta cells of the pancreas, and on vascular dysfunction. In
      addition, an ancillary study is planned to assess if metformin will improve tissue-specific
      insulin resistance in type 1 diabetes using a hyperinsulinemic euglycemic clamp.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c from baseline to 26 weeks, adjusted for baseline hemoglobin A1c.</measure>
    <time_frame>0-26 weeks</time_frame>
    <description>Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total daily dose of insulin (TDI) per kg</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipids</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>0-26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>0-13 weeks and 0-26 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>change in liver enzymes and serum creatinine</measure>
    <time_frame>0-26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of severe hypoglycemia</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of diabetic ketoacidosis</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of gastrointestinal side-effects including stomach discomfort, diarrhea, nausea/vomiting, indigestion, flatulence.</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of lactic acidosis</measure>
    <time_frame>26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in adipocytokines</measure>
    <time_frame>0-26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in androgen levels in females</measure>
    <time_frame>0-26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>0-26-weeks</time_frame>
    <description>Measured with mixed meal tolerance test among participants with evidence of residual C-peptide on a non-fasting C-peptide at screening</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in vascular dysfunction</measure>
    <time_frame>0-26 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 2000 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A central pharmacy will compound a placebo to match the metformin tablets.
The placebo product will contain the following components:
Micosolle™, silica based excipient
Silicified Micro Crystalline Cellulose, National Formulary
Safflower Oil, United States Pharmacopeia
K-30 Povidone Powder
Magnesium Stearate, National Formulary (Vegetable source)
Fumed Silica, National Formulary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin (glucophage)</intervention_name>
    <description>The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <arm_group_label>Oral Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of presumed autoimmune type 1 diabetes (T1D) as indicated by age of
             diagnosis &lt;10 years or documented positive diabetes-related autoantibodies.

             a. Note: For randomization, presence of at least one of the diabetes-related
             autoantibodies [Insulin autoantibodies (IAA) at diagnosis prior to initiation of
             insulin, Islet cell antibodies (ICA), Anti-GAD (GAD65), Anti-IA2 (IA2), Zinc
             Transporter 8 (ZnT8)] must be documented either from medical records or new laboratory
             measurement (IAA and ICA not measured by central lab) sent to central lab for
             participants who were ≥10 years old at diagnosis.

          2. Age: 12 to &lt;20 years.

          3. Duration of type 1 diabetes: ≥1 years.

          4. Current insulin regimen involves either use of an insulin pump or multiple daily
             injections of insulin (at least 3 shots per day) for the last three months, with no
             plans to switch the modality of insulin administration during the next 6 months (e.g.,
             injection user switching to a pump, pump user switching to injections).

          5. Hemoglobin A1c: 7.5% - &lt;10.0% from point of care measurement or local lab on day of
             screening visit or within 1 month prior.

          6. BMI: ≥85th percentile adjusted for age and sex .

          7. Total daily dose of insulin: ≥0.8 units per kg per day.

          8. Average of ≥3 Self-Monitoring Blood Glucose (SMBG) tests per day prior to initiating
             study and from download of study-provided blood glucose meter following screening
             visit.

          9. Available for at least 6 months of follow-up, has home phone (or access to phone), and
             willing to be contacted by clinical site staff.

         10. Expected to comply with protocol in investigator's judgment.

        Exclusion Criteria:

          1. Use of non-insulin medications for blood glucose control within prior 6 months or
             planning to use within next 6 months (other than study drug).

          2. Use of medications for weight reduction (such as: Belviq (lorcaserin), Qsymia
             (Phentermine + topiramate), Orlistat (xenical)) within the prior 6 months or planning
             to use within next 6 months.

          3. Use of a medication such as stimulants, psychotropic agents and oral/inhaled
             glucocorticoids that could affect weight gain or glycemic control of T1D or planning
             to use within the next 6 months.

          4. Any condition that in the judgment of the investigator will adversely affect the
             completion of the protocol.

          5. Females: pregnant, lactating, or intending to become pregnant within the next 34 weeks

               -  A negative urine pregnancy test will be required for all females An effective
                  contraceptive method or abstinence will be required for all females who have
                  experienced menarche

               -  Requirements regarding pregnancy testing prior to enrollment and monitoring for
                  pregnancy over the course of the study may be further defined by each individual
                  Institutional Review Board (IRB)

          6. Clinical diagnosis of celiac disease that is in poor control as defined by most recent
             tissue transglutaminase (tTG) that is in the abnormal range.

          7. History of ≥1 diabetic ketoacidosis events in the past 3 months.

          8. History of ≥1 severe hypoglycemic events (cognitive impairment that required
             assistance to treat) in the past 3 months.

          9. History of anemia or vitamin B12 deficiency in the past 2 years.

         10. Participation in an intervention study in the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kellee Miller, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Libman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Childrens Hospital of University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Nadeau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado Denver/Childrens Hospital Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jaeb Center for Health Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003 Oct;26(10):2871-5.</citation>
    <PMID>14514594</PMID>
  </reference>
  <reference>
    <citation>Kaminski BM, Klingensmith GJ, Beck RW, Tamborlane WV, Lee J, Hassan K, Schatz D, Kollman C, Redondo MJ; Pediatric Diabetes Consortium. Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr. 2013 Apr;162(4):736-740.e1. doi: 10.1016/j.jpeds.2012.09.017. Epub 2012 Oct 23.</citation>
    <PMID>23092524</PMID>
  </reference>
  <reference>
    <citation>Liu LL, Lawrence JM, Davis C, Liese AD, Pettitt DJ, Pihoker C, Dabelea D, Hamman R, Waitzfelder B, Kahn HS; SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes. 2010 Feb;11(1):4-11. doi: 10.1111/j.1399-5448.2009.00519.x. Epub 2009 May 15.</citation>
    <PMID>19473302</PMID>
  </reference>
  <reference>
    <citation>Valerio G, Iafusco D, Zucchini S, Maffeis C; Study-Group on Diabetes of Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2012 Jul;97(1):99-104. Epub 2012 Feb 13.</citation>
    <PMID>22336634</PMID>
  </reference>
  <reference>
    <citation>Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998 Jul 8;280(2):140-6. Erratum in: JAMA 1998 Nov 4;280(17):1484.</citation>
    <PMID>9669786</PMID>
  </reference>
  <reference>
    <citation>Rodriguez BL, Dabelea D, Liese AD, Fujimoto W, Waitzfelder B, Liu L, Bell R, Talton J, Snively BM, Kershnar A, Urbina E, Daniels S, Imperatore G; SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010 Aug;157(2):245-251.e1. doi: 10.1016/j.jpeds.2010.02.021. Epub 2010 Apr 14.</citation>
    <PMID>20394942</PMID>
  </reference>
  <reference>
    <citation>Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010 Feb;95(2):513-21. doi: 10.1210/jc.2009-1756. Epub 2009 Nov 13.</citation>
    <PMID>19915016</PMID>
  </reference>
  <reference>
    <citation>Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct;26(10):2923-8.</citation>
    <PMID>14514603</PMID>
  </reference>
  <reference>
    <citation>Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res. 2009 Apr;50 Suppl:S335-9. doi: 10.1194/jlr.R800059-JLR200. Epub 2008 Nov 23. Review.</citation>
    <PMID>19029122</PMID>
  </reference>
  <reference>
    <citation>Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb;28(2):301-6.</citation>
    <PMID>15677783</PMID>
  </reference>
  <reference>
    <citation>Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005 May;28(5):1051-6.</citation>
    <PMID>15855566</PMID>
  </reference>
  <reference>
    <citation>Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987 Jun 27;294(6588):1651-4.</citation>
    <PMID>3113569</PMID>
  </reference>
  <reference>
    <citation>Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987 Apr 1;59(8):750-5.</citation>
    <PMID>3825934</PMID>
  </reference>
  <reference>
    <citation>Snell-Bergeon JK, Hokanson JE, Kinney GL, Dabelea D, Ehrlich J, Eckel RH, Ogden L, Rewers M. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord. 2004 Dec;28(12):1594-9.</citation>
    <PMID>15467773</PMID>
  </reference>
  <reference>
    <citation>Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005 Feb 15;111(6):747-53. Epub 2005 Feb 7.</citation>
    <PMID>15699257</PMID>
  </reference>
  <reference>
    <citation>Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003 May;26(5):1374-9.</citation>
    <PMID>12716791</PMID>
  </reference>
  <reference>
    <citation>Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005 Jun 28;111(25):3489-93.</citation>
    <PMID>15983263</PMID>
  </reference>
  <reference>
    <citation>Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):720-6.</citation>
    <PMID>8640398</PMID>
  </reference>
  <reference>
    <citation>Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004 Feb;27(2):530-7.</citation>
    <PMID>14747240</PMID>
  </reference>
  <reference>
    <citation>Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986 Jul 24;315(4):215-9.</citation>
    <PMID>3523245</PMID>
  </reference>
  <reference>
    <citation>Arslanian S, Heil BV, Kalhan SC. Hepatic insulin action in adolescents with insulin-dependent diabetes mellitus: relationship with long-term glycemic control. Metabolism. 1993 Mar;42(3):283-90.</citation>
    <PMID>8487645</PMID>
  </reference>
  <reference>
    <citation>Heptulla RA, Stewart A, Enocksson S, Rife F, Ma TY, Sherwin RS, Tamborlane WV, Caprio S. In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res. 2003 May;53(5):830-5.</citation>
    <PMID>12702748</PMID>
  </reference>
  <reference>
    <citation>Hiatt WR, Huang SY, Regensteiner JG, Micco AJ, Ishimoto G, Manco-Johnson M, Drose J, Reeves JT. Venous occlusion plethysmography reduces arterial diameter and flow velocity. J Appl Physiol (1985). 1989 May;66(5):2239-44.</citation>
    <PMID>2745287</PMID>
  </reference>
  <reference>
    <citation>Regensteiner JG, Popylisen S, Bauer TA, Lindenfeld J, Gill E, Smith S, Oliver-Pickett CK, Reusch JE, Weil JV. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med. 2003;8(3):169-75.</citation>
    <PMID>14989557</PMID>
  </reference>
  <reference>
    <citation>Urbina EM, Wadwa RP, Davis C, Snively BM, Dolan LM, Daniels SR, Hamman RF, Dabelea D. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. J Pediatr. 2010 May;156(5):731-7, 737.e1. doi: 10.1016/j.jpeds.2009.11.011. Epub 2010 Jan 25.</citation>
    <PMID>20097360</PMID>
  </reference>
  <reference>
    <citation>Wadwa RP, Urbina EM, Anderson AM, Hamman RF, Dolan LM, Rodriguez BL, Daniels SR, Dabelea D; SEARCH Study Group. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2010 Apr;33(4):881-6. doi: 10.2337/dc09-0747. Epub 2010 Jan 12.</citation>
    <PMID>20067960</PMID>
  </reference>
  <reference>
    <citation>Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes. 2007 Aug;8(4):193-8.</citation>
    <PMID>17659060</PMID>
  </reference>
  <reference>
    <citation>Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, Atchison JA, Chiarelli F, Daneman D, Dinesen B, Dorchy H, Garandeau P, Greene S, Hoey H, Kaprio EA, Kocova M, Martul P, Matsuura N, Schoenle EJ, Søvik O, Swift PG, Tsou RM, Vanelli M, Aman J. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes. Diabet Med. 1998 Sep;15(9):752-9.</citation>
    <PMID>9737804</PMID>
  </reference>
  <reference>
    <citation>Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2003 Jan;26(1):138-43.</citation>
    <PMID>12502670</PMID>
  </reference>
  <reference>
    <citation>Cusi D, Bianchi G. A primer on the genetics of hypertension. Kidney Int. 1998 Aug;54(2):328-42. Review.</citation>
    <PMID>9690199</PMID>
  </reference>
  <reference>
    <citation>Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011 Aug;96(8):E1262-7. doi: 10.1210/jc.2011-0555. Epub 2011 Jun 1.</citation>
    <PMID>21632811</PMID>
  </reference>
  <reference>
    <citation>Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, Kibirige M, Mathew V, Matyka K, McGovern A, Stirling H, Tetlow L, Wales J, Wright N, Clayton P, Hall C. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013 Jan;98(1):322-9. doi: 10.1210/jc.2012-2710. Epub 2012 Nov 21.</citation>
    <PMID>23175691</PMID>
  </reference>
  <reference>
    <citation>Tarkun I, Dikmen E, Cetinarslan B, Cantürk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw. 2010 Dec;21(4):272-7. doi: 10.1684/ecn.2010.0217. Epub 2010 Dec 3.</citation>
    <PMID>21126943</PMID>
  </reference>
  <reference>
    <citation>Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002 May;45(5):623-34. Epub 2002 Apr 4. Review.</citation>
    <PMID>12107742</PMID>
  </reference>
  <reference>
    <citation>Regensteiner JG, Bauer TA, Reusch JE. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. Diabetes Care. 2005 Dec;28(12):2877-83.</citation>
    <PMID>16306548</PMID>
  </reference>
  <reference>
    <citation>Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2010 Feb;95(2):722-30. doi: 10.1210/jc.2009-1985. Epub 2009 Dec 8.</citation>
    <PMID>19996308</PMID>
  </reference>
  <reference>
    <citation>Montanari G, Bondioli A, Rizzato G, Puttini M, Tremoli E, Mussoni L, Mannucci L, Pazzucconi F, Sirtori CR. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol Res. 1992 Jan;25(1):63-73.</citation>
    <PMID>1738759</PMID>
  </reference>
  <reference>
    <citation>Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, Pagliaccia F, Nerla R, Di Franco A, Manto A, Rocca B, Lanza GA, Crea F, Ghirlanda G. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metab. 2013 May;15(5):427-31. doi: 10.1111/dom.12041. Epub 2012 Dec 5.</citation>
    <PMID>23167274</PMID>
  </reference>
  <reference>
    <citation>Bailey CJ. Metformin: a multitasking medication. Diab Vasc Dis Res. 2008 Sep;5(3):156. doi: 10.3132/dvdr.2008.026.</citation>
    <PMID>18777487</PMID>
  </reference>
  <reference>
    <citation>Liebson PR. Diabetes control and cardiovascular risk, Part II: Intensive glucose control--UKPDS follow-up. Prev Cardiol. 2009 Winter;12(1):51-8.</citation>
    <PMID>19301692</PMID>
  </reference>
  <reference>
    <citation>Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010 May;53(5):809-20. doi: 10.1007/s00125-009-1636-9. Epub 2010 Jan 8. Review.</citation>
    <PMID>20057994</PMID>
  </reference>
  <reference>
    <citation>Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003 Oct;149(4):323-9.</citation>
    <PMID>14514347</PMID>
  </reference>
  <reference>
    <citation>TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29.</citation>
    <PMID>22540912</PMID>
  </reference>
  <reference>
    <citation>Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2012 Feb;35(2):327-33. doi: 10.2337/dc11-1582. Epub 2011 Dec 16.</citation>
    <PMID>22179958</PMID>
  </reference>
  <reference>
    <citation>Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009 Feb;10(1):5-13. doi: 10.1111/j.1399-5448.2008.00450.x. Epub 2008 Aug 20.</citation>
    <PMID>18721166</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.</citation>
    <PMID>20393934</PMID>
  </reference>
  <reference>
    <citation>Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8.</citation>
    <PMID>18779236</PMID>
  </reference>
  <reference>
    <citation>Dabelea D, D'Agostino RB Jr, Mason CC, West N, Hamman RF, Mayer-Davis EJ, Maahs D, Klingensmith G, Knowler WC, Nadeau K. Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia. 2011 Jan;54(1):78-86. doi: 10.1007/s00125-010-1911-9. Epub 2010 Oct 1.</citation>
    <PMID>20886205</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 10, 2017</submitted>
    <returned>April 20, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

